The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock decreased 1.75% or $0.81 during the last trading session, reaching $45.35. About 177,860 shares traded or 56.16% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since March 21, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04The move comes after 5 months negative chart setup for the $1.16B company. It was reported on Mar, 21 by Barchart.com. We have $43.99 PT which if reached, will make NASDAQ:IFRX worth $34.92 million less.
INGENICO GROUP SA ORDINARY SHARES (OTCMKTS:INGIF) had a decrease of 21.71% in short interest. INGIF’s SI was 230,500 shares in March as released by FINRA. Its down 21.71% from 294,400 shares previously. It closed at $62.75 lastly. It is down 0.00% since March 21, 2018 and is . It has underperformed by 4.37% the S&P500.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update – Nasdaq” on March 21, 2019, also Nasdaq.com with their article: “Aid workers rush to rescue African cyclone victims amid mounting death toll – Nasdaq” published on March 21, 2019, Nasdaq.com published: “WENDEL : 2018 Full-Year Results – Nasdaq” on March 21, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “NoHo Partners Plc issues EUR 25 million hybrid bond – NASDAQ.com – Nasdaq” published on March 21, 2019 as well as Nasdaq.com‘s news article titled: “Mechel Reports the FY2018 Financial Results – Nasdaq” with publication date: March 21, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.16 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on April, 4. After $-0.31 actual earnings per share reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 41.94% negative EPS growth.
More notable recent Ingenico Group – GCS (OTCMKTS:INGIF) news were published by: Seekingalpha.com which released: “Ingenico Exiting Iran Created A Buying Opportunity – Seeking Alpha” on July 29, 2018, also Seekingalpha.com with their article: “Ingenico Is Still A Great Company, But More Than Ever A Long-Term Play – Seeking Alpha” published on October 11, 2016, Seekingalpha.com published: “Ingenico: Investing In The Future Of Plastic Money With A Value Play – Seeking Alpha” on June 30, 2017. More interesting news about Ingenico Group – GCS (OTCMKTS:INGIF) were released by: Seekingalpha.com and their article: “The Nest Egg Portfolio: Rubis Complies With U.S. Sanctions – A Buying Opportunity? – Seeking Alpha” published on October 06, 2018 as well as Seekingalpha.com‘s news article titled: “Ingenico Group ADR 2017 Q4 – Results – Earnings Call Slides – Seeking Alpha” with publication date: February 23, 2018.